TrialClinical lymphoma, myeloma & leukemia2019

Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia.

Abhishek Maiti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.